RedHill Doses First Patient for ERADICATE Study - Analyst Blog
19 Décembre 2013 - 1:00AM
Zacks
RedHill Biopharma Ltd. (RDHL) announced
that the first patient has been dosed in the phase III ERADICATE Hp
study. This study evaluates the safety and efficacy of RHB-105 as a
first-line treatment for confirmed Helicobacter pylori (H. pylori)
bacterial infection.
The randomized, double-blind, placebo-controlled, phase III
study is expected to enrol 90 subjects. These patients will be
randomized in a 2:1 ratio to receive either RHB-105 or placebo for
a period of 14 days.
The primary endpoint of the study is the eradication of H.
pylori infection in a span of 28 to 56 days after completion of
treatment. RedHill Biopharma expects data from this study by the
third quarter of 2014.
H. pylori is a major cause of chronic gastritis, peptic ulcer
disease and gastric cancer; and mucosa associated lymphoid tissue
(MALT) lymphoma. As per the company, H. pylori affects two-thirds
of the world’s population.
RedHill Biopharma has another interesting candidate in RHB-104.
In Nov 2013, the company commenced a double-blind,
placebo-controlled, phase III MAP U.S. study on RHB-104 for the
treatment of Crohn's disease. Apart from Crohn’s disease, RedHill
Biopharma is also evaluating the candidate for the treatment of
multiple sclerosis (phase IIa proof of concept trial is going on)
and rheumatoid arthritis (plans for a phase IIa proof of concept
trial), and systemic lupus erythematosus.
RedHill Biopharma carries a Zacks Rank #2 (Buy). Some
better-ranked stocks include Questcor Pharmaceuticals
Inc. (QCOR), Actelion
Ltd. (ALIOF) and Jazz Pharmaceuticals
plc (JAZZ). Each stock carries a Zacks Rank #1
(Strong Buy).
ACTELION LTD (ALIOF): Get Free Report
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report
QUESTCOR PHARMA (QCOR): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
(USOTC:ALIOF)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
(USOTC:ALIOF)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about (OTCMarkets): 0 recent articles
Plus d'articles sur Actelion Ltd. (PC)